

# Karim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5300331/publications.pdf>

Version: 2024-02-01

138  
papers

19,452  
citations

23567

58  
h-index

12597

132  
g-index

145  
all docs

145  
docs citations

145  
times ranked

14768  
citing authors

#	ARTICLE	IF	CITATIONS
1	Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 352-360.	27.0	1,588
2	Olaparib for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2091-2102.	27.0	1,327
3	Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 700-712.	10.7	1,280
4	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , 2016, 34, 1402-1418.	1.6	1,089
5	Lutetium-177â€“PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 1091-1103.	27.0	1,042
6	Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 2465-2474.	27.0	782
7	Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 1235-1246.	27.0	621
8	Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 40-47.	1.6	577
9	Guidelines on Testicular Cancer: 2015 Update. <i>European Urology</i> , 2015, 68, 1054-1068.	1.9	538
10	Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 686-700.	10.7	496
11	Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates. <i>Journal of Clinical Oncology</i> , 2009, 27, 1564-1571.	1.6	491
12	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018, 73, 178-211.	1.9	488
13	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2345-2357.	27.0	440
14	Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2506-2518.	27.0	403
15	Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. <i>European Urology</i> , 2016, 70, 256-262.	1.9	355
16	Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 1132-1142.	27.0	341
17	Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. <i>European Urology</i> , 2019, 75, 88-99.	1.9	333
18	Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1652-1659.	1.6	332

#	ARTICLE	IF	CITATIONS
19	Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. <i>Clinical Cancer Research</i> , 2020, 26, 2487-2496.	7.0	273
20	Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2â€‰Ã—â€‰2 factorial design. <i>Lancet</i> , The, 2022, 399, 1695-1707.	13.7	261
21	Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2197-2206.	27.0	253
22	Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trialâ€™FIRSTANA. <i>Journal of Clinical Oncology</i> , 2017, 35, 3189-3197.	1.6	251
23	Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. <i>New England Journal of Medicine</i> , 2020, 383, 1040-1049.	27.0	225
24	Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. <i>Cancer Cell</i> , 2020, 38, 489-499.e3.	16.8	216
25	Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 787-794.	10.7	206
26	Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. <i>Journal of Clinical Oncology</i> , 2016, 34, 3005-3013.	1.6	202
27	Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients. <i>European Urology</i> , 2020, 78, 195-206.	1.9	192
28	Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 572-580.	1.6	187
29	Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1740-1747.	1.6	184
30	Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. <i>Lancet Oncology</i> , The, 2014, 15, 1147-1156.	10.7	181
31	Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 509-521.	10.7	174
32	Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. <i>Lancet Oncology</i> , The, 2014, 15, 1442-1450.	10.7	163
33	Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2429-2435.	1.6	157
34	Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. <i>European Urology</i> , 2015, 68, 228-235.	1.9	144
35	Prostate cancer: ESMO Consensus Conference Guidelines 2012. <i>Annals of Oncology</i> , 2013, 24, 1141-1162.	1.2	137
36	Docetaxel and prednisone with or without lenalidomide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 417-425.	10.7	137

#	ARTICLE	IF	CITATIONS
37	Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel. <i>European Journal of Cancer</i> , 2014, 50, 1617-1627.	2.8	133
38	Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5. <i>Journal of Clinical Oncology</i> , 2015, 33, 723-731.	1.6	127
39	Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. <i>Journal of Clinical Oncology</i> , 2015, 33, 1356-1363.	1.6	120
40	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1563-1574.	1.6	108
41	Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2007, 8, 994-1000.	10.7	103
42	Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. <i>European Urology</i> , 2015, 68, 196-204.	1.9	102
43	Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. <i>Nature Medicine</i> , 2022, 28, 144-153.	30.7	102
44	Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. <i>European Urology</i> , 2020, 78, 822-830.	1.9	99
45	High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting. <i>European Journal of Cancer</i> , 2015, 51, 2570-2577.	2.8	91
46	Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology</i> , The, 2018, 19, e696-e708.	10.7	90
47	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. <i>European Journal of Cancer</i> , 2021, 146, 30-47.	2.8	81
48	Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. <i>Lancet Oncology</i> , The, 2021, 22, 402-410.	10.7	79
49	Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).. <i>Journal of Clinical Oncology</i> , 2019, 37, 142-142.	1.6	76
50	Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. <i>European Urology</i> , 2015, 68, 850-858.	1.9	74
51	Tumor Growth Rate Provides Useful Information to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD Phase 3 Trial Data. <i>European Urology</i> , 2014, 65, 713-720.	1.9	71
52	Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis. <i>European Journal of Cancer</i> , 2018, 103, 78-87.	2.8	71
53	Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA1-LBA1.	1.6	66
54	Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2017, 76, 36-44.	2.8	64

#	ARTICLE	IF	CITATIONS
55	Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 332-340.	1.9	64
56	Patients'™ self-assessment versus investigators'™ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). <i>European Journal of Cancer</i> , 2014, 50, 953-962.	2.8	63
57	Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer. <i>European Journal of Cancer</i> , 2015, 51, 1946-1952.	2.8	63
58	ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1007-1017.	2.4	63
59	Immunotherapy discontinuation – how, and when? Data from melanoma as a paradigm. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 707-715.	27.6	57
60	Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm. <i>Journal of Clinical Oncology</i> , 2017, 35, 3525-3528.	1.6	56
61	Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2014, 50, 1602-1609.	2.8	50
62	Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study. <i>European Urology</i> , 2016, 69, 834-840.	1.9	49
63	Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2017, 71, 168-171.	1.9	48
64	Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 245-260.	1.6	45
65	Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients. , 2017, 5, 31.		45
66	Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. <i>European Urology</i> , 2018, 73, 696-703.	1.9	45
67	Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial. <i>Cancer</i> , 2017, 123, 253-262.	4.1	42
68	Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. <i>European Journal of Cancer</i> , 2019, 114, 107-116.	2.8	42
69	Toxicities Following Treatment with Bisphosphonates and Receptor Activator of Nuclear Factor- $\kappa$ B Ligand Inhibitors in Patients with Advanced Prostate Cancer. <i>European Urology</i> , 2014, 65, 278-286.	1.9	41
70	Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors. <i>European Journal of Cancer</i> , 2016, 61, 44-51.	2.8	40
71	A Risk-adapted Study of Cisplatin and Etoposide, with or Without Ifosfamide, in Patients with Metastatic Seminoma: Results of the GETUG S99 Multicenter Prospective Study. <i>European Urology</i> , 2014, 65, 381-386.	1.9	39
72	Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents. <i>Clinical Cancer Research</i> , 2016, 22, 5713-5721.	7.0	37

#	ARTICLE	IF	CITATIONS
73	Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. <i>Journal of Clinical Oncology</i> , 2020, 38, 3032-3041.	1.6	37
74	Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. <i>Lancet Oncology</i> , The, 2020, 21, 1513-1525.	10.7	35
75	Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: a report from the PETRUS prospective study. <i>Oncotarget</i> , 2016, 7, 55069-55082.	1.8	33
76	Locoregional symptoms in patients with de novo metastatic prostate cancer: Morbidity, management, and disease outcome. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 202.e9-202.e17.	1.6	31
77	Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. <i>European Journal of Cancer</i> , 2016, 69, 151-157.	2.8	31
78	Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial. <i>European Journal of Cancer</i> , 2022, 160, 61-71.	2.8	29
79	Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 85-92.	0.8	28
80	Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. <i>Future Oncology</i> , 2022, 18, 425-436.	2.4	28
81	An Accessible and Unique Insight into Metastasis Mutational Content Through Whole-exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer. <i>European Urology Oncology</i> , 2020, 3, 498-508.	5.4	27
82	PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3-3.	1.6	27
83	Compliance with guidelines and correlation with outcome in patients with advanced germ-cell tumours. <i>European Journal of Cancer</i> , 2014, 50, 1284-1290.	2.8	26
84	Fatigue and physical activity in cancer survivors: A cross-sectional population-based study. <i>Cancer Medicine</i> , 2019, 8, 2535-2544.	2.8	26
85	The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 5000-5000.	1.6	25
86	Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre. <i>European Journal of Cancer</i> , 2017, 79, 185-192.	2.8	24
87	Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?. <i>Cancer Treatment Reviews</i> , 2021, 97, 102204.	7.7	24
88	Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors. <i>Gynecologic Oncology</i> , 2016, 142, 452-457.	1.4	23
89	High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. <i>Anticancer Research</i> , 2004, 24, 2897-903.	1.1	23
90	Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer. , 2022, 10, e004191.		23



#	ARTICLE	IF	CITATIONS
91	Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes. <i>JAMA Oncology</i> , 2020, 6, 206.	7.1	22
92	KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2021, 17, 3291-3299.	2.4	22
93	Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol. <i>BMC Cancer</i> , 2017, 17, 549.	2.6	19
94	Germ cell tumors in patients infected by the human immunodeficiency virus. <i>Cancer</i> , 2001, 92, 1460-1467.	4.1	18
95	Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe. <i>European Urology</i> , 2015, 67, 904-912.	1.9	18
96	Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial. <i>European Urology Focus</i> , 2017, 3, 606-614.	3.1	18
97	ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS383-TPS383.	1.6	18
98	Circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide post-chemotherapy (phase 3 AFFIRM study).. <i>Journal of Clinical Oncology</i> , 2015, 33, 5035-5035.	1.6	15
99	A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS5072-TPS5072.	1.6	15
100	Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study. <i>European Journal of Cancer</i> , 2022, 162, 56-64.	2.8	14
101	Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome. <i>European Journal of Cancer</i> , 2020, 129, 117-122.	2.8	12
102	Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. <i>Clinical Cancer Research</i> , 2021, 27, 6677-6686.	7.0	12
103	Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial. <i>European Urology</i> , 2022, 81, 234-240.	1.9	12
104	Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?. <i>Journal of Clinical Oncology</i> , 2022, 40, 3011-3014.	1.6	12
105	Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097813.	3.2	11
106	PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer. <i>Drugs</i> , 2022, 82, 719-733.	10.9	10
107	Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials. <i>European Journal of Cancer</i> , 2020, 125, 142-152.	2.8	7
108	Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT).. <i>Journal of Clinical Oncology</i> , 2019, 37, 141-141.	1.6	7

#	ARTICLE	IF	CITATIONS
109	Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1081-e1088.	1.9	6
110	Abiraterone in metastatic castration-resistant prostate cancer: Efficacy and safety in unselected patients. <i>Cancer Treatment and Research Communications</i> , 2018, 17, 37-42.	1.7	6
111	Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 444-451.	1.9	6
112	Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021. <i>European Urology</i> , 2021, 80, 4-6.	1.9	6
113	Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects. <i>European Journal of Cancer</i> , 2021, 159, 87-97.	2.8	6
114	Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. <i>European Journal of Cancer</i> , 2021, 159, 237-246.	2.8	6
115	New agents in metastatic prostate cancer. <i>European Journal of Cancer</i> , 2009, 45, 379-380.	2.8	4
116	Treatment of Castration-naive Metastatic Prostate Cancer. <i>European Urology Focus</i> , 2017, 3, 518-521.	3.1	2
117	Post Hoc Health-Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies. <i>Oncologist</i> , 2021, 26, e1179-e1188.	3.7	2
118	Nonhormone Therapy for Metastatic Castration-Resistant Prostate Cancer: Chemotherapy, Bone-Targeted Treatments, and Others. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e161-e165.	3.8	2
119	Evaluation of circulating tumor cells (CTCs) enumeration and 18F-Choline positron emission tomography/computed tomography (FCH PET/CT) as early efficacy response biomarkers in metastatic castration-resistant prostate cancer (CRPC) patients (pts) treated with abiraterone acetate.. <i>Journal of Clinical Oncology</i> , 2012, 30, 63-63.	1.6	2
120	Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5017-5017.	1.6	2
121	Estimation of Overall Survival with Subsequent Treatment Effect by Applying Inverse Probability of Censoring Weighting in the LATITUDE Study. <i>European Urology Open Science</i> , 2022, 36, 51-58.	0.4	2
122	Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 825-832.	0.8	2
123	One Size Does Not Fit All: Can We Choose the Best Sequence of Treatment in Asymptomatic Castration-resistant Prostate Cancer Patients?. <i>European Urology</i> , 2014, 66, 653-654.	1.9	1
124	Nonfamilial Chronic Serum Alpha-Fetoprotein Increase in a Patient With Clinical Stage IÂSeminoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e91-e93.	1.9	1
125	Biennial report on genitourinary cancers. <i>European Journal of Cancer</i> , 2016, 66, 125-130.	2.8	1
126	Overview of Systemic Therapy Augmenting Management of High-risk Localized Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 168-170.	3.1	1



#	ARTICLE	IF	CITATIONS
127	Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. JNCI Cancer Spectrum, 2020, 4, pkaa003.	2.9	1
128	Validation of a prognostic classification system for mediastinal nonseminomatous germ-cell tumors (MGCT).. Journal of Clinical Oncology, 2014, 32, 4562-4562.	1.6	1
129	Programmed death-ligand 1 (PD-L1) expression in cured and not cured testicular and other germ cell tumors (GCT).. Journal of Clinical Oncology, 2016, 34, 485-485.	1.6	1
130	Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?. European Urology, 2015, 68, 802-804.	1.9	0
131	Clinical News. British Journal of Hospital Medicine (London, England: 2005), 2017, 78, 368-371.	0.5	0
132	Reply to C. Ren et al. Journal of Clinical Oncology, 2018, 36, 2354-2356.	1.6	0
133	A Case of Heavily Pretreated Metastatic Germ Cell Tumor With Ongoing Long-term Complete Response After Gemcitabine Treatment. Clinical Genitourinary Cancer, 2019, 17, e485-e487.	1.9	0
134	Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. <a href="https://doi.org/10.1016/j.eururo.2020.07.032">https://doi.org/10.1016/j.eururo.2020.07.032</a> . Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Cas. European Urology, 2021, 79, e12-e13.	1.9	0
135	ARAMIS trial: Efficacy and safety phase 3 trial of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).. Journal of Clinical Oncology, 2015, 33, TPS5080-TPS5080.	1.6	0
136	Bone turnover marker (BTM) levels and clinical outcomes in advanced cancer patients (pts) treated with antiresorptive bone therapies.. Journal of Clinical Oncology, 2015, 33, e22236-e22236.	1.6	0
137	First prospective, open-label, phase 2 study of sipuleucel-T (sip-T) in European men with metastatic, castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2015, 33, e16015-e16015.	1.6	0
138	Disease burden and outcome in metastatic hormone sensitive prostate cancer (mHSPC).. Journal of Clinical Oncology, 2015, 33, 5052-5052.	1.6	0